臨床泌尿器科69巻12号

2015年11月発行

特集 いまさら聞けない！泌尿器がん化学療法の理論と実践 Ⅳ．疾患別がん化学療法の理論と実践

膀胱がん

著者： 遠藤勇気¹ 木村剛¹ 近藤幸尋¹

所属機関： ¹日本医科大学付属病院泌尿器科

ページ範囲：P.1041 - P.1050

要旨　浸潤性膀胱がんに対する根治治療として膀胱全摘術は確立されているが，膀胱全摘術後の再発率は50％前後であり，まだまだ十分なものとは言い難い。術後の局所再発・遠隔転移に対しては化学療法が行われており，シスプラチンがキードラッグとなっている。周術期化学療法については，術前化学療法の有効性が示され，術後化学療法においても確立しつつある。全身化学療法については，一次化学療法は確立されているが，二次化学療法は確立されていない。そのような状況のなかで新規保険適用薬が増え，選択肢の幅が増えた。また，新規分子標的薬の有効性が期待されており，動向が期待される分野である。

参考文献

1）がん研究振興財団：Cancer statistics in Japan 2014

2）Yafi F, North S and Kassouf W：First and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 18：e25-34, 2011

3）EAU guide line for MIBC, 2015

4）Galsky MD, Hahn NM, Rosenberg J, et al：A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12：211-214, 2011

5）Stenzl A, Cowan NC, De Santis M, et al：The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 55：815-825, 2009

6）Sternberg CN, Yagoda A, Scher HI, et al：Preliminary results of M-VAC（methotrexate, vinblastine, doxorubicin and cisplatin）for transitional cell carcinoma of the urothelium. J Urol 133：403-407, 1985

7）Loehrer PJ Sr, Einhorn LH, Elson PJ, et al：A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma：a cooperative group study. J Clin Oncol 10：1066-1073, 1992

8）Saxman SB, Propert KJ, Einhorn LH, et al：Long-term follow-up of a phase Ⅲ intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma：a cooperative group study. J Clin Oncol 15：2564-2569, 1997

9）Logothetis CJ, Dexeus FH, Finn L, et al：A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8：1050-1055, 1990

10）Sternberg CN, de Mulder PH, Schornagel JH, et al：Randomized phase Ⅲ trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin（MVAC）chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors：European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19：2638-2646, 2001

11）Sternberg CN, de Mulder P, Schornagel JH, et al：Seven year up-date of an EORTC phase Ⅲ trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42：50-54, 2006

12）Bamias A, Aravantinos G, Deliveliotis C, et al：Docetaxel and cisplatin with granulocyte colony-stimulating factor（G-CSF）versus MVAC with G-CSF in advanced urothelial carcinoma：a multicenter, randomized, phase Ⅲ study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22：220-228, 2004

13）von der Maase H, Sengelov L, Roberts JT, et al：Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23：4602-4608, 2005

14）von der Maase H, Hansen SW, Roberts JT, et al：Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer：results of a large, randomized, multinational, multicenter, phase Ⅲ study. J Clin Oncol 18：3068-3077, 2000

15）Bellmunt J, Guillem V, Paz-Ares L, et al：Phase Ⅰ-Ⅱ study of pacli-taxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18：3247-3255, 2000

16）Bellmunt J, von der Maase H, Mead GM, et al：Randomized phase Ⅲ study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy：EORTC Intergroup Study 30987. J Clin Oncol 30：1107-1113, 2012

17）Petrioli R, Frediani B, Manganelli A, et al：Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase Ⅱ study. Cancer 77：344-351, 1996

18）Bellmunt J, Ribas A, Eres N, et al：Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80：1966-1972, 1997

19）Dogliotti L, Carteni G, Siena S, et al：Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium：results of a randomized phase 2 trial. Eur Urol 52：134-141, 2007

20）Dreicer R, Manola J, Roth BJ, et al：Phase Ⅲ trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100：1639-1645, 2004

21）NCCN guideline for MIBC, 2014-2

22）日本泌尿器科学会（編）：膀胱癌診療ガイドライン2015年版．医学図書出版，東京，2015

23）ESMO guideline for MIBC, 2014

24）Bellmunt J, Choueiri TK, Fougeray R, et al：Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28：1850-1855, 2010

25）NCCN guide line for Lung Cancer, 2015

26）Bellmunt J, Fougeray R, Rosenberg JE, et al：Long-term survival results of a randomized phase Ⅲ trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 24：1466-1472, 2013

27）Han KS, Joung JY, Kim TS, et al：Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 98：86-90, 2008

28）Terakawa T, Miyake H, Yokoyama N, et al：Clinical outcome of paclitaxel and carboplatin as Second-Line chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line therapy with gemcitabine and cisplatin. Uroogia Int 92：180-185, 2014

29）Gupta S and Mahipal A：Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Contral 20：200-210, 2013

30）Fechner G, Siener R, Reimann M, et al：Randomised phase Ⅱ trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma（AUO Trial AB 20/99）. Int J Clin Pract 60：27-31, 2006

31）Albers P, Park SI, Niegisch G, et al：Randomized phase Ⅲ trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer：short-term versus prolonged treatment［German Association of Urological Oncology（AUO）trial AB 20/99］. Ann Oncol 22：288-294, 2011

32）Hussain MH, MacVicar GR, Petrylak DP, et al：Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma：results of a multicenter phase Ⅱ National Cancer Institute trial. J Clin Oncol 25：2218-2224, 2007

33）Hahn NM, Stadler WM, Zon RT, et al：Phase Ⅱ trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma：Hoosier Oncology Group GU 04-75. J Clin Oncol 29：1525-1530, 2011

34）Sandy Srinvas, et al：ASCO GU 2015. abstract 294. Phase Ⅱ study of pazopanib with weekly paclitaxel in refractory urothelial cancer.

35）Stein JP and Skinner DG：Radical cystectomy for invasive bladder cancer：long-term results of a standard procedure. World J Urol 24：296-304, 2006

36）Ghoneim MA, El-Mekresh MM, Mokhtar AA, et al：A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 85：811-816, 2000

37）Sternberg CN, Pansadoro V, Calabro, et al：Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97：1644-1652, 2003

38）Wijkstrom H, Norming U, Lagerkvist M, et al：Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma：a long-term follow-up of 276 consecutive patients. Br J Urol 81：686-691, 1998

39）Wallace DM, Raghavan D, Kelly KA, et al：Neo-adjuvant（pre-emptive）cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67：608-615, 1991

40）Neoadjuvant chemotherapy in invasive bladder cancer：a systematic review and meta-analysis. Lancet 361：1927-1934, 2003

41）Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer：update of a systematic review and meta-analysis of individual patient data advanced bladder cancer（ABC）meta-analysis collaboration. Eur Urol 48：202-205, 2005

42）Winquist E, Kirchner TS, Segal R, et al：Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder：a systematic review and metaanalysis. J Urol 171：561-569, 2004

43）Stein JP, Lieskovsky G, Cote R, et al：Radical cystectomy in the treatment of invasive bladder cancer：long-term results in 1,054 patients. J Clin Oncol 19：666-675, 2001

44）Bassi P, Ferrante GD, Piazza N, et al：Prognostic factors of outcome after radical cystectomy for bladder cancer：a retrospective study of a homogeneous patient cohort. J Urol 161：1494-1497, 1999

45）Logothetis CJ, Johnson DE, Chong C, et al：Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer：an update. J Clin Oncol 6：1590-1596, 1988

46）Studer UE, Bacchi M, Biedermann C, et al：Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer：results of a prospective randomized trial. J Urol 152：81-84, 1994

47）Skinner DG, Daniels JR, Russell CA, et al：The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer：a prospective comparative trial. J Urol 145：459-464, 1991

48）Stockle M, Meyenburg W, Wellek S, et al：Advanced bladder cancer（stages pT3b, pT4a, pN1 and pN2）：improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148：302-306, 1992

49）Bono AV, Benvenuti C, Gibba A, et al：Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol Ital 11：5-8, 1997

50）Cognetti F, Ruggeri EM, Felici M, et al：Adjuvant chemotherapy（AC）with cisplatin＋gemcitabine（CG）versus chemotherapy（CT）at relapse（CR）in patients（pts）with muscle-invasive bladder cancer（MIBC）submitted to radical cystectomy（RC）. An Italian multicenter randomised phase Ⅲ trial. J Clin Oncol 26：5023, 2008

51）Paz-Ares LG, Solsona E, Esteban E, et al：Randomized phase Ⅲ trial comparing adjuvant paclitaxel/gemcitabine/cisplatin（PGC）to observation in patients with resected invasive bladder cancer：results of the Spanish Oncology Genitourinary Group（SOGUG）99/01 study. J Clin Oncol 28：82, 2010

52）Leow JJ, Martin-Doyle W and Rajagopal PS：Adjuvant chemotherapy for invasive bladder cancer：a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66：42-54, 2014

53）Sternberg CN, Skoneczna I and Kerst JM：Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N＋M0 urothelial carcinoma of the bladder（EORTC 30994）：an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16：76-86, 2015